Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2986392 | 1.00 | MAPK1 (0.44) | MAPK1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL19821988 | 0.81 | LMNA (0.31) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL24412963 | 0.77 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL20924831 | 0.77 | — | — | |
| SCHEMBL5549609 | 0.75 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL2394341 | 0.75 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL16914172 | 0.73 | — | — | |
| SCHEMBL16914210 | 0.73 | — | — | |
| SCHEMBL10997994 | 0.73 | — | — | |
| SCHEMBL12057715 | 0.72 | CA1 (0.45) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777032-B2 | N-4-[3-Chloro-4-(3-fluoro-benzyloxy)-phenyl]-N6-(3-ethyl-oxazolidin-2-ylidene)-quinazoline-4,6-diamine; use as type I receptor tyrosine kinase inhibitor; hyperproliferation diseases such as cancer; antiinflammatory agents | ARRAY BIOPHARMA INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-7585975-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7501427-B2 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ARRAY BIOPHARM, INC. (US) | 2008-08-14 | — | — | US | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194558-A1 | Quinazoline analogs as receptor Tyrosine Kinase inhibitors | ABL1, ERBB2, FLT3 | MAPK1 130/4885LMNA 4234/4885CNR1 723/4885 |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ABL1, ERBB2, FLT3 | MAPK1 130/4885LMNA 4234/4885CNR1 723/4885 |
| US-20090270621-A1 | QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS | ABL1, ERBB2, FLT3 | MAPK1 130/4885LMNA 4234/4885CNR1 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.